US FDA approves Revances Botox rival
The US approval of Daxxify was based on a late-stage trial of over 2,700 patients that showed the injection had a six-month median duration, with some patients even showing the effect at nine months. Revance Therapeutics said on Thursday it had received the U.S. Food and Drug Administration's approval for its injection that could rival AbbVie's Botox. The company said Daxxify, its treatment for wrinkles that appear as people become older, has the ability to address the duration of treatment effect, which it believes is the greatest unmet need among the class of injections. The U.S. approval of Daxxify was based on a late-stage trial of over 2,700 patients that showed the injection had a six-month median duration, with some patients even showing the effect at nine months. The company received a "complete response letter" in November last year after the regulator pointed to "deficiencies" at its manufacturing site during an inspection

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!